(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public ...

Anthem Biosciences files for a $397 million IPO amid India’s record-breaking year for public listings. The Bengaluru-based ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.

The latest health updates include Anthem Biosciences' IPO, France's bird flu outbreaks impacting disease-free status, China's ...

Indian contract drugmaker Anthem Biosciences files for $397 million IPO amid booming Indian market for public offerings.

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion ...

The IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling ...

Anthem Biosciences has filed for a Rs 3,395-crore IPO consisting entirely of an offer for sale by promoters and shareholders. The funds will not benefit the company directly but go to selling parties.

Indian drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers ...

Anthem Biosciences, a CRDMO specializing in drug discovery, development and manufacturing, has filed draft papers with Sebi ...

The proposed initial public offer (IPO) is entirely an offer for sale (OFS) worth ₹3,395 crore by promoters, investors and ...